Entera Bio
Entera Bio's revenue fell 76.8% to $0 million in fiscal 2025. Its operating margin was −27,450.0%, down from −5,295.6% a year earlier. Free cash flow was −$7 million. The diluted share count rose 22.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Entera Bio does
Entera Bio is a drug developer based in Jerusalem, Israel, that is working to turn protein and peptide drugs, which today are almost always given by injection, into tablets that patients can swallow. Its technology, called N-Tab, is meant to protect these large molecules in the gut and help them pass into the bloodstream. It has no approved products and no sales yet.
Its most advanced drug candidate, EB613, is an oral version of teriparatide, a bone-building osteoporosis drug that Eli Lilly sells as the injection Forteo. Entera plans a final-stage (Phase 3) study of EB613 in postmenopausal women with osteoporosis, using the change in hip bone density as the main measure. Its other candidates include EB612, an oral treatment for hypoparathyroidism, a rare disorder that leaves too little calcium in the blood; an oral long-acting version of the same hormone; an oral GLP-1/glucagon tablet for obesity, developed with OPKO Health; and an oral GLP-2 tablet for short bowel syndrome. It says these would compete with injected drugs such as Ascendis Pharma's Yorvipath and Gattex.
Entera is small: at the end of 2025 it had 22 employees, all of its full-time staff in Israel. It has no sales force of its own and says it depends on deals with partners to develop and sell its products.
Its biggest risks, as it describes them
- Its auditor has raised substantial doubt about its ability to keep going, and it needs more money to fund its studies.
- Its drugs are all still in development and may fail in trials or never win approval.
- Delays in starting or finishing the planned Phase 3 study of EB613.
- Depending on partners to develop and sell its drugs, and on a few key staff.
- Other companies' drugs, or another way to make peptide tablets, could prove better than its own.
Income statement
Entera Bio lost money in fiscal 2025: a net loss of $11 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 25 | 12 | 11 | 9 | 7 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 8.0x | 9.6x | 10.3x | 7.6x | 6.9x |
| Quick ratio | 8.0x | 9.6x | 10.3x | 7.6x | 6.9x |
Cash flow
Projections
Project Entera Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 5 insiders bought $140,880 of Entera Bio shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Geno J GermanoDirector | Bought | 20,000 | $1.30 | $26,000 | Form 4 |
| Mar 5, 2026 | Sean EllisDirector | Bought | 10,000 | $1.23 | $12,300 | Form 4 |
| Feb 12, 2026 | Steven D RubinDirector | Bought | 5,000 | $1.49 | $7,450 | Form 4 |
| Feb 10, 2026 | Geno J GermanoDirector | Bought | 20,000 | $1.49 | $29,800 | Form 4 |
| Feb 10, 2026 | Haya TaitelDirector | Bought | 7,500 | $1.48 | $11,100 | Form 4 |
| Feb 9, 2026 | Sean EllisDirector | Bought | 18,000 | $1.24 | $22,320 | Form 4 |
| Feb 9, 2026 | Steven D RubinDirector | Bought | 10,000 | $1.20 | $12,000 | Form 4 |
| Dec 29, 2025 | Miranda Jayne ToledanoChief Executive Officer, Director | Bought | 11,000 | $1.81 | $19,910 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | −17,879.2% |
| Altman Z'' | −20.43 | −34.49 | −20.27 |
| Accruals ratio | −12.7% | −25.7% | −32.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | Fail |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | — | — |
Compare
Put Entera Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Entera Bio | FY25 | −76.8% | −27,450.0% | −17,802.4% | — | — | — | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Revenue growth | — | — | — | −52.8% | 54.7% | 56.4% | −76.5% | −100.0% | — | −76.8% |
| Gross profit | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 3 | 3 | 8 | 7 | 6 | 7 | 6 | 4 | 4 | 6 |
| Operating income | −5 | −11 | −11 | −12 | −11 | −12 | −13 | −9 | −10 | −12 |
| Net income | −1 | −11 | −10 | −11 | −11 | −12 | −13 | −9 | −10 | −11 |
| Diluted EPS (US$) | 0.78 | 2.49 | 1.31 | 0.89 | — | — | — | — | — | — |
| Diluted shares (millions) | 7 | 4 | 8 | 12 | 19 | 26 | 29 | 29 | 38 | 46 |
| Cash flow | ||||||||||
| Cash from operations | −3 | −4 | −10 | −9 | −11 | −9 | −12 | −7 | −7 | −7 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −3 | −5 | −10 | −9 | −11 | −9 | −13 | −7 | −7 | −7 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 5 | 1 | 2 | 1 | 2 | 2 | 2 | 3 | 3 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 4 | 12 | 8 | 15 | 9 | 25 | 12 | 11 | 9 | 7 |
| Debt incl. finance leases | — | 4 | — | — | — | — | — | — | — | — |
| Total assets | — | 13 | 13 | 17 | 10 | 26 | 13 | 12 | 9 | 16 |
| Total liabilities | — | 45 | 3 | 5 | 2 | 3 | 1 | 1 | 1 | 3 |
| Shareholders' equity | −25 | −32 | 10 | 14 | 8 | 23 | 12 | 10 | 8 | 13 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | 11.0% | 17.8% | 34.7% | 24.6% | — | 5.0% | 0.0% |
| Operating margin | — | — | −2,172.2% | −4,853.4% | −3,059.7% | −2,139.6% | −9,714.2% | — | −5,295.6% | −27,450.0% |
| Net margin | — | — | −2,060.8% | −4,574.1% | −3,072.9% | −2,134.3% | −9,754.5% | — | −5,271.3% | −27,235.7% |
| Free cash flow margin | — | — | −1,972.8% | −3,796.2% | −2,906.8% | −1,590.2% | −9,362.7% | — | −3,768.5% | −17,802.4% |
| Rule of 40 (growth + FCF margin) | — | — | — | −3,849.0% | −2,852.2% | −1,533.8% | −9,439.2% | — | — | −17,879.2% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | −90.4% | −105.4% | −81.0% | −76.2% | −80.3% | −103.3% | −108.0% |
| Return on assets | — | — | −77.4% | −71.9% | −84.9% | −68.3% | −66.8% | −71.4% | −90.2% | −90.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |